What role does albumin play in paclitaxel's cell membrane interaction?

How does albumin bind to paclitaxel?

Albumin binds paclitaxel through hydrophobic pockets that capture the drug's nonpolar parts. The binding keeps paclitaxel in solution without toxic solvents. Albumin itself then engages receptors on cancer cells such as gp60 and SPARC, helping the molecule enter cells through caveolae-mediated transcytosis.

When does albumin help paclitaxel cross the cell membrane?

Albumin helps paclitaxel cross the cell membrane mainly through receptor-mediated transcytosis. Once albumin-paclitaxel complexes bind to gp60 receptors, the membrane folds inward to form vesicles that shuttle the drug into the cell. This process avoids direct diffusion across the lipid bilayer.

What happens if albumin is removed from the paclitaxel formulation?

Without albumin, paclitaxel requires Cremophor EL and ethanol as solvents. These solvents cause hypersensitivity reactions and neuropathy. They also alter cell membrane fluidity, interference with micelle formation, and reduced uptake compared with the albumin-bound form.

How does albumin-bound paclitaxel differ from solvent-based versions?

Albumin-bound paclitaxel bypasses solvent-induced membrane effects. Solvent-based versions disrupt lipid packing and register high rates of infusion reactions. Albumin-bound versions enter cells through receptor-driven pathways that appear less disruptive to membranes and produce fewer immediate reactions.

Can albumin help avoid solvent-related membrane disruption?

Yes. Albumin replaces toxic solvents by solubilizing paclitaxel through protein binding. The protein itself participates in membrane interactions via receptor-mediated transport, so the drug enters cells without forcing changes in lipid bilayer structure.

What patents cover albumin-bound paclitaxel?

Patents covering albumin-bound paclitaxel cover both the composition and the delivery method. Several key patents expired between 2015 and 2020. [1]